R A C S Pharmachem (India) Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 12 Year, 23 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.68 Cr
- Revenue Growth 54.25%
- Profit Growth 28.78%
- Ebitda -3.30%
- Net Worth 21.62%
- Total Assets 14.75%
About R A C S Pharmachem (India)
R A C S Pharmachem (India) Private Limited (RACSPIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 30 January 2013 and has a history of 12 years. Its registered office is in Kolar, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹6.68 Cr.
Jagannadha Chinthalapati, Naga Kunadharaju, and Delampady Holla serve as directors at the Company.
Company Details
- Location
Kolar, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232KA2013PTC067680
- Company No.
067680
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jan 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at R A C S Pharmachem (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jagannadha Chinthalapati  | Managing Director | 30-Jan-2013 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Naga Kunadharaju | Director | 30-Jan-2013 | Current |
| Delampady Holla | Director | 14-Dec-2020 | Current |
Financial Performance of R A C S Pharmachem (India).
R A C S Pharmachem (India) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 54.25% increase. The company also saw a substantial improvement in profitability, with a 28.78% increase in profit. The company's net worth Soared by an impressive increase of 21.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of R A C S Pharmachem (India)?
In 2023, R A C S Pharmachem (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹66.80 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 6.68 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Oct 2024 | Canara Bank | ₹2.10 Cr | Open |
| 04 Sep 2014 | Canara Bank | ₹4.58 Cr | Open |
How Many Employees Work at R A C S Pharmachem (India)?
R A C S Pharmachem (India) has a workforce of 34 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of R A C S Pharmachem (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped R A C S Pharmachem (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
